Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Zinc recalled?

Yes — there is an active recall. 47 ongoing FDA recalls mention Zinc (156 total). Check the affected lots below.

Most common reason: cGMP deviation (53 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Zinc. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Zinc recalls in 2026

12 initiated in 2026, 156 in total — newest first
Class II · Moderate risk

Zicam

CGMP Deviations; FDA inspection of the contract manufacturer noted out of limit results for microbiological testing

Ongoing Microbial contamination Church & Dwight Co., Inc. D-0790-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0642-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0641-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0637-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0636-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0635-2026
Class II · Moderate risk

Rapidol

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0633-2026
Class II · Moderate risk

Lil Drug Store

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0632-2026
Class II · Moderate risk

Circle K

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0631-2026
Class II · Moderate risk

Lucky Super Soft

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0630-2026
Class II · Moderate risk

Nivagen

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals NDC 75834-170-02 D-0209-2026
Class II · Moderate risk

Nivagen

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals NDC 75834-170-01 D-0208-2026
Class II · Moderate risk

WeCare

cGMP deviations

Ongoing cGMP deviation Blossom Pharmaceuticals NDC 67777-223-05 D-0205-2026